Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation: A case report with long term follow-up outcomes

RATIONALE: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) remains a major therapeutic challenge. In recent years, new molecular-targeted therapies, such as cabozantinib, have been approved for the treatment of advanced HCC. However, clinical experience with these new d...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahn, Robert, Sadeghlar, Farsaneh, Bartels, Alexandra, Zhou, Taotao, Weismüller, Tobias, Kupczyk, Patrick, Meyer, Carsten, Gaertner, Florian C., Toma, Marieta, Vilz, Tim, Knipper, Petra, Glowka, Tim, Manekeller, Steffen, Kalff, Jörg, Strassburg, Christian P., Gonzalez-Carmona, Maria A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462617/
https://www.ncbi.nlm.nih.gov/pubmed/34559100
http://dx.doi.org/10.1097/MD.0000000000027082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462617/
https://www.ncbi.nlm.nih.gov/pubmed/34559100
http://dx.doi.org/10.1097/MD.0000000000027082

Ejemplares similares